程序性细胞死亡蛋白1配体2在胸腺瘤及胸腺瘤型重症肌无力患者中的表达

Expression of Programmed Cell Death 1 Ligand 2 in Patients With Thymoma and Thymomatous Myasthenia Gravis.

作者信息

Zhu Haoshuai, Zou Jianyong, Zeng Bo, Yang Lei, Xiao Jiefei, Zhang Xin, Feng Yanfen, Su Chunhua

机构信息

Department of Thoracic Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Am J Clin Pathol. 2022 Nov 3;158(5):646-654. doi: 10.1093/ajcp/aqac108.

DOI:10.1093/ajcp/aqac108

PMID:36208149

Abstract

OBJECTIVES

This study aimed to examine the expression of programmed cell death 1 ligand 2 (PD-L2) in thymoma and thymomatous myasthenia gravis (MG).

METHODS

The records of 70 patients with thymoma receiving surgical resection between January 2017 and December 2018 were retrospectively reviewed. Thymoma PD-L2 expression was evaluated by immunohistochemistry staining. Associations between PD-L2 expression and clinicopathologic features were examined.

RESULTS

PD-L2 expression was positive in 41 patients (58.6%) and negative in 29 patients (41.4%). Of them, 33 had thymomatous MG. Patients with MG were more likely to be 50 years of age or younger (69.70% vs 35.14%); have more World Health Organization (WHO) type B thymomas (84.85% vs 64.86%); have tumors of smaller size (4.09 ± 2.33 cm vs 6.47 ± 2.42 cm); have positive PD-L2 expression (78.79% vs 40.54%); and have a higher percentage of PD-L2-positive cells, higher PD-L2 expression intensity, and score (all P < .05). Positive PD-L2 expression was associated with more type B thymomas, higher Masaoka-Koga stage, smaller tumor size, ectopic thymus, and MG (all P < .05). Factors significantly associated with MG were age under 50 years, tumor size less than 5 cm, and positive PD-L2 expression (all P < .05).

CONCLUSIONS

Thymoma PD-L2 expression is significantly associated with thymomatous MG and WHO histologic types B2 and B3.

摘要

目的

本研究旨在检测程序性细胞死亡1配体2（PD-L2）在胸腺瘤及胸腺瘤型重症肌无力（MG）中的表达情况。

方法

回顾性分析2017年1月至2018年12月期间70例行手术切除的胸腺瘤患者的病历资料。采用免疫组织化学染色评估胸腺瘤中PD-L2的表达情况。检测PD-L2表达与临床病理特征之间的相关性。

结果

41例患者（58.6%）PD-L2表达呈阳性，29例患者（41.4%）呈阴性。其中，33例患有胸腺瘤型MG。MG患者更可能年龄在50岁及以下（69.70%对35.14%）；世界卫生组织（WHO）B型胸腺瘤更多（84.85%对64.86%）；肿瘤体积更小（4.09±2.33 cm对6.47±2.42 cm）；PD-L2表达呈阳性（78.79%对40.54%）；且PD-L2阳性细胞百分比更高、PD-L2表达强度更高及评分更高（均P<0.05）。PD-L2阳性表达与更多的B型胸腺瘤、更高的Masaoka-Koga分期、更小的肿瘤体积、异位胸腺及MG相关（均P<0.05）。与MG显著相关的因素为年龄小于50岁、肿瘤体积小于5 cm及PD-L2表达阳性（均P<0.05）。